Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Assertio Holdings is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 5.1 for the broader beat in this window.
Last mentioned: Mar 13, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Assertio Holdings is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 5.1 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 6.1 in the same window. We currently track 1 Healthcare story that mention Rolvedon, all published on March 13, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Rolvedon. Shared-story counts are live from our verified record — not editorial picks.
Perspective Therapeutics and Assertio Holdings are set to report Q4 2025 results, highlighting a divergence between the high-growth radiopharmaceutical sector and the specialty pharma market. Investors are focused on Perspective's clinical pipeline progress and Assertio's efforts to stabilize its commercial portfolio.
Source: Seeking Alpha · Seeking Alpha
Rolvedon is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
